Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Corthera, Inc.(formerly BAS Medical, Inc.), a member of the Novartis group of companies
This is an international, randomized, double-blind, placebo-controlled, Phase II/III trial of intravenous recombinant relaxin for the treatment of signs and symptoms in patients hospitalized for acute decompensated heart failure. The Phase II pilot study has completed; the Phase III main portion of the trial is ongoing.
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Hospitalized for acute heart failure
Dyspnea at rest or with minimal exertion
Pulmonary congestion
Able to provide informed consent
Systolic blood pressure \> 125 mmHg
Impaired renal function defined as an eGFR of 30-75 mL/min/1.73m2